1. Lee WJ, Moon IJ, Lee SH, Won CH, Chang SE, Choi JH, et al. Cutaneous anaplastic large-cell lymphoma (ALCL): a comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site. J Am Acad Dermatol. 2016; 74:1135–1143. PMID:
26897385.
Article
2. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008; 111:5496–5504. PMID:
18385450.
Article
3. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park). 2010; 24:574–587. PMID:
20669794.
4. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013; 85:206–215. PMID:
22789917.
Article
5. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012; 83:293–302. PMID:
22440390.
Article
6. Rochet NM, Markovic SN, Porrata LF. The role of complete blood cell count in prognosis-watch this space. Oncol Hematol Rev. 2012; 8:76–82.
Article
7. Chang IW, Chen HK, Ma MC, Huang WT. Anaplastic large cell lymphoma with paraneoplastic leukocytosis: a clinicopathological analysis of five cases. APMIS. 2011; 119:794–801. PMID:
21995633.
Article
8. Kim HS, Sim SJ, Kim DC, Kim JS, Song KH, Kim KH. A case of ALK-negative systemic anaplastic large cell lymphoma. Ann Dermatol. 2004; 16:125–131.
Article
9. El-Osta HE, Salyers WJ, Jr , Palko W, Hagan ME, El-Haddad B, Schulz TK. Anaplastic large-cell lymphoma with leukemoid reaction. J Clin Oncol. 2008; 26:4356–4358. PMID:
18779625.
Article
10. Sueki Y, Nozaki Y, Kawashima I, Yamamoto T, Nakajima K, Mitumori T, et al. Anaplastic large cell lymphoma with paraneoplastic neutrophilia: an association between IL-17 elevation and aggressive disease progression. Int J Hematol. 2014; 99:773–776. PMID:
24609719.
Article